ArticleOpen biology2016
CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells.
Article in Open biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 72 citations in OpenAlex.
- CCL5 exposure promotes acute and transient megakaryopoiesis and hematopoietic progenitor expansion.Stem cell reports · 2026Article
- Unveiling CCL5: the master regulator of breast cancer progression and immune evasion.Breast cancer research : BCR · 2026Review
- SFRP2 drives aerobic glycolysis and tumor progression in ovarian cancer by transcriptional upregulation of PTK2B.Journal of translational medicine · 2026Article
- CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma.Journal of translational medicine · 2026Article
- Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.Signal transduction and targeted therapy · 2026Article
- The impact of lipid metabolism remodeling in the tumor microenvironment on angiogenesis.Discover oncology · 2026Review
- Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.Frontiers in immunology · 2025Review
- New insight into a simple high-yielding method for the production of fully folded and functional recombinant human CCL5.Scientific reports · 2024Article
- YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma.Virchows Archiv : an international journal of pathology · 2023Article
- Association between abnormal lipid metabolism and tumor.Frontiers in endocrinology · 2023Review
- CCL4 participates in the reprogramming of glucose metabolism induced by ALV-J infection in chicken macrophages.Frontiers in microbiology · 2023Article
- Multifaceted role of chemokines in solid tumors: From biology to therapy.Seminars in cancer biology · 2022Review
- A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer.Scientific reports · 2022Article
- CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.Breast cancer research : BCR · 2022Article
- CCL5 Deficiency Enhanced Cryo-Thermal-Triggered Long-Term Anti-Tumor Immunity in 4T1 Murine Breast Cancer.Biomedicines · 2022Article
- Multi‑faceted role of cancer‑associated adipocytes in the tumor microenvironment (Review).Molecular medicine reports · 2021Review
- Article
- IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In earlier studies, we showed that CCL5 enhances proliferation and survival of MCF-7 breast cancer cells in an mTOR-dependent manner and we provided evidence that, for T cells, CCL5 activation of CCR5 results in increased glycolysis and enhanced ATP production. Increases in metabolic activity of cancer cells, specifically increased glycolytic activity and increased expression of glucose transporters, are associated with tumour progression. In this report, we provide evidence that CCL5 enhances the proliferation of human breast cancer cell lines (MDA-MB-231, MCF-7) and mouse mammary tumour cells (MMTV-PyMT), mediated by CCR5 activation. Concomitant with enhanced proliferation we show that CCL5 increases cell surface expression of the glucose transporter GLUT1, and increases glucose uptake and ATP production by these cells. Blocking CCL5-inducible glucose uptake abrogates the enhanced proliferation induced by CCL5. We provide evidence that increased glucose uptake is associated with enhanced glycolysis, as measured by extracellular acidification. Moreover, CCL5 enhances the invasive capacity of these breast cancer cells. Using metabolomics, we demonstrate that the metabolic signature of CCL5-treated primary mouse mammary tumour cells reflects increased anabolic metabolism. The implications are that CCL5-CCR5 interactions in the tumour microenvironment regulate metabolic events, specifically glycolysis, to promote tumour proliferation and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.